QDENGA® (TAK-003): A Breakthrough in Dengue Vaccination

Dengue is one of the world's most important mosquito borne viral diseases and is caused by four closely related but distinct dengue virus serotypes: DENV 1, DENV 2, DENV 3 and DENV 4. Infection may range from mild febrile illness to severe dengue which can result in bleeding, organ impairment and death. The presence of multiple serotypes has made the development of a safe and effective dengue vaccine particularly challenging.

QDENGA® (TAK 003) is a live attenuated tetravalent dengue vaccine developed by Takeda. It is designed to stimulate an immune response against dengue caused by the four serotypes and received WHO prequalification in May 2024.

In a significant development for India, QDENGA® became the first dengue vaccine approved in India in July 2026 following scientific evaluation of its quality, safety and efficacy by the Central Drugs Standard Control Organisation (CDSCO).

What is QDENGA®?

In India, CDSCO has authorized QDENGA® for the prevention of dengue disease in individuals aged 4 to 60 years with two 0.5 mL doses administered three months apart.

QDENGA® uses an attenuated DENV 2 strain as its genomic backbone with recombinant constructs expressing surface proteins representing DENV 1, DENV 3 and DENV 4. This approach enables the vaccine to present antigens from all four serotypes to the immune system.

How does QDENGA® work?

• Live attenuated vaccine technology QDENGA® contains weakened dengue viruses designed to stimulate immunity without causing dengue disease in healthy vaccine recipients.
• Tetravalent immune response The vaccine presents components representing all four dengue serotypes promoting the development of antibodies and cellular immune responses.
• Immune memory Following vaccination the immune system develops immunological memory enabling a faster and more effective response when exposed to dengue virus in the future.
• Broad serotype coverage A major challenge in dengue vaccination is achieving meaningful protection across different serotypes. QDENGA® was specifically developed as a tetravalent vaccine to address this challenge.

What makes QDENGA® different?

Vaccination does not replace mosquito control measures. Dengue prevention requires an integrated approach involving vector control, disease surveillance, appropriate case management and community education.

Clinical Evidence: The TIDES Program

The Tetravalent Immunization against Dengue Efficacy Study (TIDES) was a major Phase 3 randomized, placebo controlled trial involving more than 20,000 children and adolescents aged 4 to 16 years across dengue endemic countries in Asia Pacific and Latin America. Participants received two doses three months apart.

Key findings

• 80.2% efficacy against virologically confirmed dengue during the primary efficacy period.
• 90.4% efficacy against hospitalized dengue during the relevant secondary analysis.
• Efficacy was demonstrated in participants who were both seropositive and seronegative at baseline although performance varied according to serotype and baseline serostatus.
• At approximately 4.5 years of follow up cumulative efficacy was 61.2% against virologically confirmed dengue and 84.1% against hospitalized dengue.

These findings highlight the potential value of QDENGA® while also demonstrating the importance of evaluating vaccine performance according to dengue serotype and previous exposure.

Evidence from India

The Indian clinical development program included a Phase III study (DEN 302; NCT06060067) evaluating the safety and immune response to QDENGA® in healthy children, adolescents and adults aged 4 to 60 years in India. The study enrolled approximately 480 participants and evaluated a two dose schedule administered three months apart.

This India specific clinical evidence contributed to the regulatory evaluation supporting the country's first dengue vaccine approval.

Why is this important for India?

India experiences a substantial dengue burden with transmission occurring across many regions and showing considerable seasonal variation. The approval of QDENGA® in July 2026 therefore represents an important development in dengue prevention.

Potential significance

• Provides a new preventive tool against dengue disease.
• It is designed to provide protection against disease caused by all four dengue virus serotypes.
• Introduces vaccination as an additional component of dengue control strategies.
• Provides an opportunity to generate further real world evidence in Indian populations.
• Highlights the role of pharmaceutical innovation in addressing endemic infectious diseases.

Following marketing authorization QDENGA® is expected to become available through private healthcare facilities in India with availability anticipated from 2027.

Pharmaceutical Significance

QDENGA® is an excellent example of translational pharmaceutical science where virology, immunology, biotechnology and regulatory science converge to address a major public health challenge.

The vaccine demonstrates how live attenuated vaccine technology can be engineered to generate immunity against multiple viral serotypes. Its development also illustrates the importance of large scale clinical evaluation, long term safety monitoring and assessment of efficacy across different populations and serological backgrounds.

For pharmacy students, QDENGA® provides an opportunity to understand the pathway from vaccine design and manufacture to clinical trials to regulatory approval to public health implementation.

Safety and Important Considerations

QDENGA® should be administered according to the approved Indian product information and applicable medical recommendations. Common vaccine related reactions are generally mild to moderate although adverse reactions can occur. Continued post marketing safety surveillance remains important including monitoring for rare hypersensitivity reactions.

Importantly, QDENGA® does not prevent every dengue infection and vaccination should not be considered a substitute for measures that reduce mosquito exposure.

WHO Recommendation and Indian Approval

The Indian regulatory indication and WHO programmatic recommendation are not identical.

In India, QDENGA® has been approved for individuals aged 4 to 60 years. WHO recommends programmatic use of TAK 003 particularly in children aged 6 to 16 years living in settings with high dengue transmission intensity with two doses administered three months apart.

This distinction highlights the importance of tailoring vaccination strategies to national epidemiology, regulatory decisions and public health priorities.

Future Perspective

The approval of QDENGA® in India marks an important step toward expanding the tools available for dengue prevention. Future priorities include evaluating:

• Real world vaccine effectiveness
• Long term protection
• Serotype specific performance
• Safety through continued surveillance
• Optimal vaccination strategies for different Indian populations

QDENGA® (TAK 003) represents an important advancement in dengue prevention through the use of a live attenuated tetravalent vaccine designed to address all four dengue virus serotypes. Clinical studies have demonstrated meaningful protection against dengue disease and hospitalization while long term studies continue to clarify its performance across different serotypes and baseline dengue exposure.

The July 2026 approval of QDENGA® in India as the country's first approved dengue vaccine adds particular significance to this pharmaceutical innovation.

More broadly, QDENGA® demonstrates how advances in virology, immunology, biotechnology and pharmaceutical sciences can be translated into practical tools for disease prevention.

● Author

Aswini P V

Department of Pharmaceutics

LinkedIn